ID   NZM089
AC   CVCL_0D49
SY   NZM89
DR   cancercelllines; CVCL_0D49
DR   Wikidata; Q54931631
RX   PubMed=32567790;
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790).
ST   Source(s): PubMed=32567790
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11,14
ST   D16S539: 11
ST   D18S51: 14,16
ST   D19S433: 13,14
ST   D21S11: 30,31.2
ST   D2S1338: 20,22
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 12
ST   FGA: 21,22
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 7
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//